Full Press Release Details
terna Zentaris Inc. 1405 du Parc-Technologique Blvd.
Qu bec (Qu bec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
terna Zentaris to Raise US$15 Million in Registered Direct Offering
Quebec City, Canada, April 15, 2010 terna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the
Company ), a late-stage drug development company specialized in oncology and endocrinology,
announced today that it has received commitments from institutional investors to purchase US$15
million of securities in a registered direct offering. Under the terms of a Securities Purchase
Agreement, the Company will sell to such institutional investors an aggregate of approximately 11.1
million common shares of its capital at a price of US$1.35 per share and issue warrants
to acquire an aggregate of approximately 4.4 million common shares at an exercise price of US$1.50
The warrants to purchase additional common shares of terna Zentaris will be exercisable six months
following their date of issuance and will expire on the fifth-year anniversary of the date on which
they become exercisable. All of the securities were offered pursuant to an effective shelf
registration statement filed in the United States. Proceeds from the transaction will be used for
general corporate purposes, including clinical development, capital expenditures and for working
capital. The offering is expected to be consummated no later than April 20, 2010, subject to
customary closing conditions.
Rodman Renshaw, LLC, a subsidiary of Rodman Renshaw Capital Group, Inc., (NASDAQ: RODM), acted
as the exclusive placement agent for the transaction.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any
securities nor shall there be any sale of such securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction. A shelf registration statement relating to the common shares and
warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has
been filed with the Securities and Exchange Commission (the SEC ) and has been declared effective.
A prospectus supplement relating to the offering will be filed by the Company with the SEC and the
Canadian securities regulatory authorities. Copies of the prospectus supplement and accompanying
prospectus may be obtained directly from the Company or by contacting terna Zentaris Inc., 1405 du
Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.
About terna Zentaris Inc.
terna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine
therapy News releases and additional information are available at
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions
of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and
unknown risks and uncertainties, which could cause the Company s actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue R D projects, the successful and
timely completion of clinical studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company s quarterly and annual
filings with the Canadian and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained herein to reflect future
results, events or developments except if we are required by a governmental authority or applicable
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406